Read-Gene (WSE:RDG) - Share price, News & Analysis

RDG fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

RDG Stock Overview

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors.

Risk Analysis

Does not have a meaningful market cap (PLN30M)

Volatile share price over the past 3 months

Does not have meaningful revenue (PLN6M)

Read-Gene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Read-Gene
Historical stock prices
Current Share Price	zł2.51
52 Week High	zł3.30
52 Week Low	zł2.20
Beta	-1.74
1 Month Change	-6.69%
3 Month Change	-10.99%
1 Year Change	-15.20%
3 Year Change	185.23%
5 Year Change	36.41%
Change since IPO	-7.04%

Shareholder Returns

	RDG	PL Biotechs	PL Market
7D	8.2%	-0.2%	1.5%
1Y	-15.2%	-38.3%	-14.0%

Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -40% over the past year.

Return vs Market: RDG matched the Polish Market which returned -15.6% over the past year.

Price Volatility

Is RDG's price volatile compared to industry and market?
RDG volatility
RDG Average Weekly Movement	10.4%
Biotechs Industry Average Movement	7.3%
Market Average Movement	6.9%
10% most volatile stocks in PL Market	13.4%
10% least volatile stocks in PL Market	4.5%

Stable Share Price: RDG is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: RDG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

Founded	Employees	CEO	Website
2005	22	Jan Lubinski	https://www.read-gene.com

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors. Its activities include chemoprevention, clinical trials, and genetic tests. Chemoprevention is the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer.

Read-Gene Fundamentals Summary

How do Read-Gene's earnings and revenue compare to its market cap?
RDG fundamental statistics
Market Cap	zł29.59m
Earnings (TTM)	-zł284.00
Revenue (TTM)	zł6.29m

4.7x

P/S Ratio

9,999x

P/E Ratio

Is RDG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
RDG income statement (TTM)
Revenue	zł6.29m
Cost of Revenue	zł803.81k
Gross Profit	zł5.49m
Other Expenses	zł5.49m
Earnings	-zł284.00

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

May 31, 2022

Earnings per share (EPS)	-0.00002
Gross Margin	87.22%
Net Profit Margin	-0.004%
Debt/Equity Ratio	0.0%

How did RDG perform over the long term?

See historical performance and comparison

Valuation

Is Read-Gene undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

8.14x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: RDG (PLN2.51) is trading above our estimate of fair value (PLN0.23)

Significantly Below Fair Value: RDG is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: RDG is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.

PE vs Market: RDG is unprofitable, so we can't compare its PE Ratio to the Polish market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RDG's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: RDG is overvalued based on its PB Ratio (8.1x) compared to the PL Biotechs industry average (4.5x).

Future Growth

How is Read-Gene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

42.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Read-Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Read-Gene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

48.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: RDG is currently unprofitable.

Growing Profit Margin: RDG is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: RDG is unprofitable, but has reduced losses over the past 5 years at a rate of 48.2% per year.

Accelerating Growth: Unable to compare RDG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: RDG has a negative Return on Equity (-0.007%), as it is currently unprofitable.

Financial Health

How is Read-Gene's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RDG's short term assets (PLN8.4M) exceed its short term liabilities (PLN422.7K).

Long Term Liabilities: RDG's short term assets (PLN8.4M) do not cover its long term liabilities (PLN12.1M).

Debt to Equity History and Analysis

Debt Level: RDG is debt free.

Reducing Debt: RDG had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable RDG has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: RDG is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 9.6% per year.

Dividend

What is Read-Gene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RDG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDG's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RDG has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Jan Lubinski

no data

Tenure

Prof, Dr. HAB. N. MED. Jan Lubinski serves as President of the Management Board at Read-Gene SA. Prof. Lubinski served as the Chief Executive Officer of Read-Gene SA.Prof. Lubinski is one of the most famo...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31